La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Korro Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Korro Bio..

Korro Bio (NASDAQ:KRRO) Azioni, Catena delle Opzioni

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Korro Bio Inc

<a href="https://www.bloomberg.com/news/articles/2024-11-15/lucid-ceo-says-unprofitable-ev-maker-is-immune-from-trump-policy-changes">https://www.bloomberg.com/news/articles/2024-11-15/lucid-ceo-says-unprofitable-ev-maker-is-immune-from-trump-policy-changes</a>
Lucid Group Inc.'s chief executive downplayed the significance of US electric vehicle tax credits for the company, even as concerns about the potential loss of subsidies sent the EV maker's shares to new lows.

News

LCID

Reported Earlier, 'Lucid CEO Says EV Maker Mostly Immune If Trump Nixes Tax Credit' - Bloomberg News

BTIG analyst Gregory Lewis maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $19.

Price Target

Analyst Ratings

Core Scientific, Inc. - Class A Common Stock

CORZ

BTIG Maintains Buy on Core Scientific, Raises Price Target to $19

WIIM

McDonalds shares are trading lower after the company announced it will spend $100 million to move past the E. Coli outbreak it experienced at some of its stores.

BTIG analyst Gregory Lewis maintains Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Buy and raises the price target from $6 to $9.

CIFR

BTIG Maintains Buy on Cipher Mining, Raises Price Target to $9

The U.S. Treasury Department has released its <a href="https://www.fincen.gov/frequently-requested-foia-processed-records">quarterly report</a>, revealing that last year, over 830 financial institutions nationwide have officially acknowledged relationships with state-licensed cannabis businesses. According to a <a href="https://norml.org/news/2024/11/14/treasury-report-over-800-banking-institutions-report-relationships-with-state-licensed-cannabis-businesses/?link_id=5&amp;can_id=23ddea46021350bb8012464da757f45b&amp;source=email-norml-news-of-the-week-11142024&amp;email_referrer=email_2530540&amp;email_subject=norml-news-of-the-week-11142024">report</a> from the National Organization for the Reform of Marijuana Laws (NORML), this number reflects a modest increase from the previous year and represents nearly double the number of banks and credit unions engaged with the cannabis sector in 2018.
However, despite this growth, fewer than 10% of all financial institutions in the U.S. currently provide services to the <a href="https://www.benzinga.com/cannabis">cannabis industry</a>. The ongoing hesitation among banks stems from federal law, which classifies marijuana as a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I controlled substance</a>. This classification poses significant legal risks for banks, even when working with businesses fully compliant with state cannabis regulations.
<h3 class="wp-block-heading">Legislative Stalemate Continues To Hinder Progress</h3>
Efforts to resolve the banking issue have <a href="https://www.benzinga.com/markets/cannabis/24/07/39730510/house-gop-divided-over-cannabis-strikes-banking-protections-from-bill-respect-the-will-of-these-">repeatedly stalled in Congress</a>. The U.S. House of Representatives has passed legislation seven times to <a href="https://www.benzinga.com/topic/secure-and-fair-enforcement-safe-banking-act">protect financial institutions</a> that serve cannabis businesses from federal penalties. Yet, the Senate has <a href="https://www.benzinga.com/markets/cannabis/24/06/39324658/gop-controlled-house-strips-cannabis-banking-protections-from-government-spending-bill-in-blow-t">failed to advance</a> these proposals to a floor vote, leaving the cannabis industry in a precarious financial position.
The lack of clear federal guidelines continues to deter many banks, exacerbating the challenges faced by cannabis businesses in securing banking services and investment capital. According to a survey by Whitney Economics, <a href="https://www.benzinga.com/markets/cannabis/22/01/25324529/survey-72-of-cannabis-operators-say-lack-of-banking-is-biggest-problem-even-fewer-are-making-pro">over 70% of cannabis operators</a> cited limited access to banking and capital as their primary obstacle.
<h3 class="wp-block-heading">Impact On Smaller And Minority-Owned Businesses</h3>
The absence of comprehensive banking reform disproportionately impacts smaller and minority-owned cannabis businesses, which often rely on traditional financing to grow and operate. NORML, the first cannabis advocacy group in U.S., has called on Congress to amend federal banking laws. "No industry can operate safely, transparently, or effectively without access to banks or other financial institutions. The players in this industry, particularly smaller and minority-owned businesses, and their consumers will remain severely hampered without better access to credit and financing," said NORML deputy director Paul Armentano.
The lack of federal legalization and banking access for cannabis has <a href="https://www.benzinga.com/markets/cannabis/23/04/31671933/is-the-cannabis-industry-ignoring-minority-communities">disproportionately impacted minorities</a> and small businesses. Many entrepreneurs, especially from marginalized communities, face significant barriers to entry in the cannabis industry due to limited access to financial services, such as loans and credit. This forces many to operate in cash, increasing risks and operational difficulties. Additionally, the continued federal prohibition contributes to <a href="https://www.benzinga.com/markets/cannabis/22/08/28566915/racism-blossoms-in-states-with-criminal-penalties-for-cannabis-possession">racial disparities in arrests</a> and convictions related to cannabis, even as legalization spreads at the state level. Without full legalization and banking reform, these barriers hinder economic opportunities for minority business owners and perpetuate systemic inequities.
<h3 class="wp-block-heading">The Path Forward: SAFER Banking Act</h3>
The <a href="https://www.benzinga.com/topic/safer-banking-act">SAFER Banking Act</a> remains a key focus for cannabis advocates, who argue that it would provide the much-needed clarity and legal protection for financial institutions willing to work with the industry. The bill&#8217;s future remains tied to the broader <a href="https://www.benzinga.com/topic/cannabis-rescheduling">debate over federal cannabis policy</a>, and advocates <a href="https://www.benzinga.com/markets/cannabis/24/10/41133218/house-democrats-urge-dea-to-speed-up-cannabis-rescheduling">continue to push for its passage</a> to ensure safer, more equitable conditions for cannabis businesses across the U.S. For now, the limited participation of banks underscores the persistent legal uncertainty surrounding cannabis, even as the industry continues to expand across state markets.
Cover image made with AI

Cannabis

Treasury Report: Over 800 Banks Partnered With Cannabis Companies In 2023 Despite Federal Hurdles

BTIG analyst Gregory Lewis maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Buy and raises the price target from $16 to $20.

BTIG Maintains Buy on Bloom Energy, Raises Price Target to $20

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) plans to challenge recent court decisions that allow several states and hundreds of school districts across the United States to proceed with lawsuits.
These legal actions accuse Meta's <a target="_blank" href="https://www.benzinga.com/news/24/10/41349398/mark-zuckerbergs-meta-to-face-lawsuits-over-teen-social-media-addiction-judge-rejects-dismissal-moti" rel="noreferrer noopener">social media platforms</a>, including Facebook and Instagram, of contributing to a mental health crisis among young users.
The company filed appeals late Thursday, seeking a review by the U.S. Ninth Circuit Court of Appeals.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41981957/meta-hit-with-841-million-eu-fine-over-antitrust-violations-tied-to-facebook-marketplace" rel="noreferrer noopener">Meta Hit With $841 Million EU Fine Over Antitrust Violations Tied To Facebook Marketplace</a>
The appeals follow separate rulings by a federal judge in California last month, which rejected Meta's requests to dismiss the lawsuits, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-15/meta-to-appeal-orders-letting-schools-states-sue-over-addiction?srnd=homepage-Americas&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>.
U.S. District Judge Yvonne Gonzalez Rogers ruled in favor of 34 state attorneys general who argued that Meta's social media platforms, Facebook and Instagram, have had detrimental effects on youth mental health, leading to claims of negligence and public harm.
However, Judge Rogers largely denied motions to dismiss negligence claims but limited specific allegations, referencing Section 230 of the Communications Decency Act.
Alongside Meta, other tech giants such as Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) were also named in lawsuits filed by various school districts.
TikTok&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/10/41243023/tiktok-gets-sued-13-states-and-dc-accuse-chinese-platform-of-boosting-corporate-profits-via-social-m" rel="noreferrer noopener">faces regulatory action</a> from&nbsp;13 U.S. states and the&nbsp;District of Columbia for allegedly harming the youth.
Meta's legal team is moving forward with the appeal. The company argues that its platforms are not directly responsible for the alleged mental health issues, citing protections under existing internet laws.
Meta, Snap, and TikTok jointly launched Thrive to <a target="_blank" href="https://www.benzinga.com/news/24/09/40846628/meta-snap-and-tiktok-come-together-to-combat-suicide-and-self-harm-content-online-will-share-signals" rel="noreferrer noopener">tackle the spread</a> of harmful content related to self-harm and suicide on their platforms.
The program enables these social media companies to share alerts about graphic content, enhancing efforts to limit its reach.
The Mental Health Coalition collaborates with companies to help address concerns and reduce the stigma around mental health issues online.
Meta reported removing over 12 million posts related to suicide and self-harm on Facebook and Instagram between April and June this year.
Recently, <a target="_blank" href="https://www.benzinga.com/general/social-media/24/11/41862616/meta-ceo-mark-zuckerberg-dodges-personal-liability-in-child-social-media-addiction-lawsuits-federal-judge-cites-lack-of-evidence" rel="noreferrer noopener">Rogers ruled</a> that Meta CEO Mark Zuckerberg is not personally liable in 25 lawsuits alleging social media addiction among children.
Judge Yvonne Gonzalez Rogers dismissed claims suggesting Zuckerberg ignored internal warnings about mental health risks on Facebook and Instagram.
The plaintiffs argued that Zuckerberg downplayed the dangers, but the judge cited insufficient evidence of his direct involvement.
The ruling only applies to claims against Zuckerberg, while similar legal challenges against Meta remain unaffected.
Price Action: META stock is down 3.73% at $555.66 at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" target="_blank" rel="noreferrer noopener">ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Legal

Tech

Media

GOOGL

SNAP

Meta Wants To Fight Back Order Allowing States and Schools To Sue Over Social Media Addiction

Brookline Capital analyst Kemp Dolliver downgrades Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) from Buy to Hold.

Downgrades

EYEN

Brookline Capital Downgrades Eyenovia to Hold

ABUS

Barinthus Biotherapeutics shares are trading lower. The company announced data from the ongoing Phase 2b HBV003 clinical trial.

DBGI

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

Citigroup analyst Keith Horowitz maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Buy and raises the price target from $50 to $55.

ALLY

Citigroup Maintains Buy on Ally Financial, Raises Price Target to $55

Investors with a lot of money to spend have taken a bearish stance on TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TDG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for TransDigm Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 60%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,689,007, and 3 are calls, for a total amount of $122,970.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $765.0 and $1325.0 for TransDigm Gr, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for TransDigm Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of TransDigm Gr's whale trades within a strike price range from $765.0 to $1325.0 in the last 30 days. 
<h3>TransDigm Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731694605_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$31.3</td>
<td>$30.6</td>
<td>$31.3</td>
<td>$1305.00</td>
<td>$356.8K</td>
<td align="right">121</td>
<td align="right">114</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$54.2</td>
<td>$52.0</td>
<td>$53.5</td>
<td>$1250.00</td>
<td>$292.5K</td>
<td align="right">0</td>
<td align="right">83</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$30.7</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$1200.00</td>
<td>$287.1K</td>
<td align="right">4</td>
<td align="right">205</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$26.8</td>
<td>$22.4</td>
<td>$26.0</td>
<td>$1200.00</td>
<td>$252.2K</td>
<td align="right">4</td>
<td align="right">103</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.0</td>
<td>$11.2</td>
<td>$17.0</td>
<td>$1265.00</td>
<td>$170.0K</td>
<td align="right">34</td>
<td align="right">102</td>
</tr>
</tbody>
</table>

<h3>About TransDigm Gr</h3>
TransDigm manufactures and services a diverse set of specialized parts for commercial and military aircraft. The firm organizes itself in three segments: power and control, airframes, and a small non-aviation segment, which serves mostly off-road vehicles and mining equipment. It operates as an acquisitive holding company that focuses its portfolio on firms that make proprietary aerospace products with substantial aftermarket demand. TransDigm regularly employs financial leverage to amplify its operating results.
Having examined the options trading patterns of TransDigm Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of TransDigm Gr</h3>
<ul>
<li>With a trading volume of 236,246, the price of TDG is up by 1.44%, reaching $1290.0.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for TransDigm Gr</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $1531.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on TransDigm Gr with a target price of $1500. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on TransDigm Gr, which currently sits at a price target of $1563. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest TransDigm Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

TransDigm Gr Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Intuit.
Looking at options history for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $224,213 and 9, calls, for a total amount of $436,947.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $560.0 to $730.0 for Intuit over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intuit's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intuit's significant trades, within a strike price range of $560.0 to $730.0, over the past month.
<h3>Intuit Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731694599_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$5.1</td>
<td>$4.2</td>
<td>$4.8</td>
<td>$730.00</td>
<td>$120.0K</td>
<td align="right">5</td>
<td align="right">451</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$89.7</td>
<td>$87.2</td>
<td>$89.6</td>
<td>$720.00</td>
<td>$71.6K</td>
<td align="right">4</td>
<td align="right">10</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$94.7</td>
<td>$91.5</td>
<td>$94.7</td>
<td>$730.00</td>
<td>$66.2K</td>
<td align="right">9</td>
<td align="right">11</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$144.5</td>
<td>$140.9</td>
<td>$142.0</td>
<td>$560.00</td>
<td>$56.8K</td>
<td align="right">5</td>
<td align="right">2</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$81.7</td>
<td>$80.0</td>
<td>$80.42</td>
<td>$610.00</td>
<td>$56.2K</td>
<td align="right">80</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Intuit</h3>
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
Having examined the options trading patterns of Intuit, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Intuit</h3>
<ul>
<li>Currently trading with a volume of 650,880, the INTU's price is down by -2.25%, now at $685.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>Professional Analyst Ratings for Intuit</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $800.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Intuit, targeting a price of $800. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuit with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

INTU

What the Options Market Tells Us About Intuit

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are lower on Thursday due to<a href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers"> news </a>that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services. This has some investors concerned because Kennedy was critical of certain vaccines and vaccinations.
Some believe the weakness in the stock may present a buying opportunity. This is why our team of expert traders and technical analysts has made it our Stock of the Day.
On Wall Street, many trading strategies and methods are based on the concept of reversion to the mean. If something goes too far one way, there is a good chance that it reverses and comes back the other way.
Most of the time, a stock stays in what is known as its trading range. But sometimes investors and traders can become emotional and aggressive. They can push the shares out of the range.
When this happens, there may be opportunities to profit. There is a good chance there will be a reversion back to the mean.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1024x529.png" alt="" class="wp-image-650959" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1536x794.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1.png 1583w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill">WHO Calls Vaccines &#8216;Absolutely Critical&#8217; As Trump&#8217;s Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill</a>
If a stock is below its typical or average range, traders say that it is &#8220;oversold.&#8221; Some anticipate a reversal back to the average. This would mean a move higher.
So, they enter the market as buyers. This could put pressure on the stock and force the price higher. It could become a self-fulfilling prophecy.
The lower part of the chart is the Relative Strength Index (RSI) momentum indicator. When the blue line crosses below the horizontal red line, it indicates oversold conditions. As you can see, that is the case now. Pfizer is very oversold.
There is also another reason why the stock may reverse and head higher.
The shares have dropped to a price level that was support in April. Stocks tend to have support at levels that had been support before. Sometimes they can even rally off of support.
There are traders and investors who sold at the support level in April and regretted doing so when the price moved higher. Some decide to buy their shares back if they can at the same price they were sold.
So, now that the shares are back to their selling price, they are placing buy orders. This creates support.
The combination of being oversold and at support means there is a good chance Pfizer reverses and heads higher.
Read Next:<a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> </a> • <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a>
Photo: Shutterstock

Biotech

Health Care

Technicals

Trading Ideas

Stock Of The Day: Is Pfizer Set Up To Rally?

Financial giants have made a conspicuous bullish move on Royal Caribbean Gr. Our analysis of options history for Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) revealed 11 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 27% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $238,532, and 8 were calls, valued at $709,157.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $240.0 for Royal Caribbean Gr, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Royal Caribbean Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Royal Caribbean Gr's whale trades within a strike price range from $120.0 to $240.0 in the last 30 days. 
<h3>Royal Caribbean Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731694594_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$117.55</td>
<td>$116.0</td>
<td>$116.0</td>
<td>$120.00</td>
<td>$232.0K</td>
<td align="right">200</td>
<td align="right">20</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$26.15</td>
<td>$24.25</td>
<td>$25.2</td>
<td>$207.50</td>
<td>$136.0K</td>
<td align="right">185</td>
<td align="right">69</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$34.0</td>
<td>$31.9</td>
<td>$32.89</td>
<td>$200.00</td>
<td>$131.4K</td>
<td align="right">458</td>
<td align="right">40</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.2</td>
<td>$220.00</td>
<td>$126.0K</td>
<td align="right">633</td>
<td align="right">301</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.3</td>
<td>$4.15</td>
<td>$4.3</td>
<td>$220.00</td>
<td>$86.0K</td>
<td align="right">633</td>
<td align="right">538</td>
</tr>
</tbody>
</table>

<h3>About Royal Caribbean Gr</h3>
Royal Caribbean is the world's second-largest cruise company, operating 68 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021.
<h3>Present Market Standing of Royal Caribbean Gr</h3>
<ul>
<li>Currently trading with a volume of 665,083, the RCL's price is down by -0.86%, now at $231.0. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>Professional Analyst Ratings for Royal Caribbean Gr</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $251.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Royal Caribbean Gr, which currently sits at a price target of $240. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Royal Caribbean Gr, targeting a price of $257. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Royal Caribbean Gr, targeting a price of $243. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Royal Caribbean Gr with a target price of $245. 
&#x2A; An analyst from Tigress Financial has decided to maintain their Buy rating on Royal Caribbean Gr, which currently sits at a price target of $270. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Royal Caribbean Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Royal Caribbean Gr's Options Market Dynamics

On Friday, Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company&#8217;s Optejet dispensing platform <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42004665/eyenovia-provides-update-on-phase-3-chaperone-study" rel="noreferrer noopener">pediatric progressive myopia</a>.
Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long.
The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years.
The DRC reviewed the safety and efficacy data from 252 evaluable patients. The DRC found that the rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo.
In the safety analysis, all dosages and placebo appeared well-tolerated, with a mild and infrequent adverse event profile. Full study data has not yet been released to Eyenovia.
&#8220;We plan to terminate the study, review the data more thoroughly, and evaluate the next steps,&#8221; stated Michael Rowe, Eyenovia&#8217;s CEO.
In light of the results of this review, the company is considering strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives.
William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/EYEN/analyst-ratings" rel="noreferrer noopener">Eyenovia to Market Perform</a>.
The analyst says,&#8221; While the approval of Mydcombi provided important validation of Eyenovia's Optejet device, and the subsequent approval of clobetasol propionate ophthalmic solution 0.05% added another promising product to the company's commercial portfolio, we believe the negative results from the CHAPERONE study and limited capital to invest in the launch of clobetasol or further pipeline programs limits near-term upside.&#8221;
Price Action: EYEN stock is down 68.2% at $0.1083 at last check Friday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42014448/teledyne-controls-eadl-xs-certified-for-boeing-737ng-aircraft-enhancing-data-security" target="_blank" rel="noreferrer noopener">Teledyne Controls&#8217; eADL XS Certified For Boeing 737NG Aircraft, Enhancing Data Security</a></li>
</ul>

Analyst Color

Equities

Movers

General

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Avicanna Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTCQX">AVCNF</a>) announced its financial results Thursday for the third quarter, disclosing revenue of CA$6.27 million ($4.49 million), compared to CA$6.25 million in the same period last year. The Toronto-based cannabis company also reported improved consolidated gross margin to 57% from 46% for the same period in 2023.
"We are pleased to report the results of another quarter showing progressive improvements across our four business pillars," stated CEO Aras Azadian. "Our continuous optimization efforts contributed to improvements in our overall financial performance, consolidated gross margins, and balance sheet. We are now better positioned to turn our attention towards our international growth initiatives and take further steps towards advancing our long-term business model."
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41998220/agrifys-q3-revenue-drop-18-6m-loss-amid-new-leadership">Agrify&#8217;s Q3 Revenue Drop, $18.6M Loss Amid New Leadership</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Q3 Financial Highlights</h2>
<ul>
<li>Gross profit was CA$3.7 million compared to CA$2.9 million in the comparable quarter last year.</li>
</ul>
<ul>
<li>Adjusted EBITDA was a loss of CA$293,931 compared to adjusted EBITDA loss of $473,650 in the corresponding period last year.</li>
<li>Net loss amounted to CA$786,388 compared to net loss of CA$1.42 million in the third quarter of 2023.</li>
<li>Fully repaid outstanding principle balance of approximately CA$1.3 million owed under non-convertible debenture.</li>
</ul>
<h2 class="wp-block-heading">Recent Milestones</h2>
In August, the biopharmaceutical company&nbsp;announced &nbsp;the <a href="https://www.benzinga.com/markets/cannabis/24/08/40403052/avicannas-cbg-products-reach-19-countries-denmark-joins-global-expansion">successful export of its Aureus-branded cannabigerol (CBG) products to Denmark</a>. This marked the 19th international market for Aureus-branded products and the 22nd market overall for Avicanna&#8217;s product range. The export was facilitated through Avicanna's majority-owned subsidiary, Santa Marta Golden Hemp SAS.
The same month, Avicanna <a href="https://www.benzinga.com/markets/cannabis/24/08/40628172/avicanna-secures-nearly-2m-in-private-placement-deal-amid-us-patent-win-for-cannabinoid-topical-">closed a non-brokered private placement</a> offering of its 6,620,692 ‎‎units at $0.30 per unit for aggregate gross proceeds of $1,986,207.
This year also, the company confirmed that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 20230025693A1, covering the company&#8217;s deep penetrating topical cannabinoid composition and methods for <a href="https://www.benzinga.com/markets/cannabis/24/08/40585810/avicanna-secures-us-patent-for-topical-cannabinoid-technology-to-treat-pain-and-inflammation" target="_blank" rel="noreferrer noopener">treating musculoskeletal inflammation and pain.</a>
<h2 class="wp-block-heading">Price Action</h2>
Avicanna shares closed Thursday's market session flat at 17 cents a share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41992549/cv-sciences-q3-revenue-stable-amid-new-launches-financing">CV Sciences Q3: Revenue Stable Amid New Launches, Financing</a></li>
</ul>
Photo: Courtesy of Avicanna

Earnings

AVCNF

Avicanna Reduces Net Loss And Improves Gross Profit, Focusing On International Markets

Money is one of the top reasons couples fight – and when one partner hasn't worked for over a decade, tensions only rise. This was the case for a woman who recently called into financial advisor <a href="https://www.benzinga.com/personal-finance/24/11/41883704/start-with-a-beater-car-says-dave-ramsey-when-youre-debt-free-and-paying-cash-for-your-dream-ride-youll-appreciate-the-sacrifice">Dave Ramsey's show</a>, seeking advice on what to do about her husband, who's been unemployed for 13 years. Despite his Ph.D. in pharmaceutical chemistry, he hasn't held a job since his layoff in 2011, leaving her as the sole breadwinner.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
As she described how they'd moved across the country, sought counseling and even enlisted resume help, Ramsey listened closely before giving her some straight talk: "This has nothing to do with the mechanics of finding a job … He doesn't want to work."
The woman explained that her husband's layoff coincided with shifts in the pharmaceutical industry and the economic crash, which made finding a comparable job difficult. But, as she's rebuilt her career, she's increasingly felt that his job search has been less than active. Ramsey laid it out: "Behavior is a language. What's he been telling you for a decade? ‘I don't work.'"
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
Co-host Dr. John Delony added that people in similar situations often take <a href="https://www.benzinga.com/startups/24/11/41852620/theres-a-great-place-to-go-when-youre-broke-to-work-says-dave-ramsey-about-a-piece-of-advice-he-got">whatever work they can find</a> to support their families. Ramsey pointed out, "I know too many people with Ph.D.s who got laid off but went to work at the grocery store or Walmart in the interim."
The caller admitted she'd encouraged him to find any job just to return to the workforce. Still, the years kept passing. Ramsey's co-host sympathized, but his message was tough: "This is about getting up off your butt." He continued, stressing that the woman's husband must feel the consequences of his inaction. "Somebody's going to have to love him enough to knock him out of the ditch," Ramsey advised, "because he ain't climbing out."
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
The situation became even trickier when she admitted she'd consulted a lawyer, only to find she might have to pay alimony if she left him. For this caller, Ramsey's advice boiled down to one central theme … love sometimes means <a href="https://www.benzinga.com/personal-finance/24/09/40838359/dave-ramsey-says-youre-wasting-5-000-a-year-if-you-spend-13-70-a-day-on-things-you-dont-need">helping someone face their reality</a>.
With the unemployment rate for Ph.D. holders aged 25 and over at just 1%, a 13-year gap in work is practically unheard of. According to Time, men without full-time jobs are 33% more likely to get divorced than those who are employed. So it's no wonder this caller is fed up with her husband's lack of ambition – her frustration is more than understandable.
Ramsey's advice cuts to the core. Without intervention, this <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">situation likely won't change</a> and the toll it takes on finances and marriage could grow harder to ignore.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Woman Says Husband With A Ph.D. Hasn't Worked In 13 Years – Dave Ramsey Tells Her To 'Love Him Enough to Knock Him Out of the Ditch'

Citigroup analyst Alicia Yap maintains Dada Nexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) with a Neutral and lowers the price target from $2 to $1.9.

DADA

Citigroup Maintains Neutral on Dada Nexus, Lowers Price Target to $1.9

Citigroup analyst Alicia Yap maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Buy and raises the price target from $108 to $115.

NTES

Citigroup Maintains Buy on NetEase, Raises Price Target to $115

RBC Capital analyst Luca Issi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $95.00. The company's s...

RBC Capital Reaffirms Their Buy Rating on Korro Bio (KRRO)

Wave stock soars 73% on positive data for RNA editing treatment (update)

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Korro Bio (KRRO – Research Report) and increased the price target to $115.0...

Promising RNA Editing Developments and KRRO-110 Potential Drive Buy Rating for Korro Bio

Raymond James initiated coverage of Korro Bio (KRRO) with a Strong Buy rating and $153 price target The firm believes RNA editing will provide bett...

Korro Bio initiated with a Strong Buy at Raymond James

RBC Capital raised the firm's price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that R...

Korro Bio price target raised to $105 from $95 at RBC Capital

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $115.00. Mitc...

Korro Bio's Promising Regulatory and Preclinical Advances Earn a Buy Rating from Analyst Mitchell Kapoor

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Korro Bio (KRRO – Research Report), Paragon 28 (FNA ...

Analysts' Top Healthcare Picks: Korro Bio (KRRO), Paragon 28 (FNA)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $180.00. The com...

Piper Sandler Reaffirms Their Buy Rating on Korro Bio (KRRO)

Korro Bio GAAP EPS of -$2.26

Korro Bio, Inc. ( ($KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors. Korro ...

Comments

Korro Bio

Korro Bio (KRRO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO